

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Proposal for resolution on decrease of the share capital to (A) cover loss; and (B) allocation to unrestricted equity

The board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 24 April 2023 resolves to decrease the share capital, partly to cover loss in accordance with A below, and partly for allocation to unrestricted equity in accordance with B below.

A. Decrease of the share capital to cover loss

The board of directors proposes that the extraordinary general meeting shall resolve on a share capital decrease of SEK 50,000,000 to cover loss and without withdrawal of shares. Through the decrease, the share capital decreases from SEK 88,613,891.20 to SEK 38,613,891.20.

B. Decrease of the share capital for allocation to unrestricted equity

The board of directors further proposes that the extraordinary general meeting shall resolve on a share capital decrease of an additional SEK 24,435,668.608 for allocation to unrestricted equity and without withdrawal of shares. The reason for the board of directors' proposal on the share capital decrease according to this item B is to improve the relation between the share capital and unrestricted equity.

As a statement under Chapter 20, Section 13 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) the board of directors states the following. The resolution on share capital decrease in accordance with the proposal in this item B can be implemented without an authorization from the Swedish Companies Registration Office (Sw. Bolagsverket) or the general court, since the company will at the same time carry out a rights issue of units, which results in that neither the company's restricted equity nor share capital together will decrease. The board of directors' proposal for a resolution to approve the board of directors' resolution on the rights issue of units is set out in item 8 on the agenda to the meeting.

Following the share capital decrease under item A above, the effect of the board of directors' proposal for a resolution on share capital decrease in accordance with this item B is that the share capital and restricted equity will decrease by SEK 24,435,668.608 to SEK 14,178,222.592, whereby at the same time the share's quota value decreases from SEK 0.40 to SEK 0.064. The effect upon full subscription of the rights issue is that the share capital and restricted equity thereafter will increase by SEK 28,234,864.384 (based on the new quota

value) to SEK 42,413,086.976. If the rights issue is only subscribed for at the guaranteed level (approximately 91.35 per cent), the share capital and restricted equity will increase by SEK 25,791,417.856 to SEK 39,969,640.448.

The resolution on share capital decrease according to A and B above shall be resolved upon as one joint resolution and presupposes and is conditional on the extraordinary general meeting resolving to amend the Articles of Association as well as to approve the board of directors' resolution on rights issue of units in accordance with the board of directors' proposal to the meeting.

The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the general meeting.

Lund in March 2023

The Board of Directors of Alligator Bioscience AB (publ)